Company Research Report: Neurocrine Biosciences, Inc.
Company Overview
Name: Neurocrine Biosciences, Inc.
Mission: Neurocrine Biosciences is dedicated to relieving the suffering of people with great needs but few options, particularly those with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.
Founding: The company was founded in 1992 by Wylie Vale, Ph.D., and Lawrence Steinman, Ph.D.
Key People:
- Kyle W. Gano, Ph.D. - Chief Executive Officer
- Matt Abernethy - Chief Financial Officer
- Eric Benevich - Chief Commercial Officer
- Dimitri E. Grigoriadis, Ph.D. - Distinguished Scholar
- Eiry W. Roberts, M.D. - Chief Medical Officer
- Julie Cooke - Chief Human Resources Officer
Headquarters: No information is available
Number of Employees: 1,200+
Revenue: No information is available
Known For: Neurocrine Biosciences is known for its FDA-approved treatments for neurological disorders such as tardive dyskinesia and chorea associated with Huntington's disease, as well as treatments for endometriosis and uterine fibroids.
Products
Neurocrine Biosciences offers several pharmaceutical products and is actively developing new treatments in key therapeutic areas:
INGREZZA® (valbenazine)
- Indications: Treatment of tardive dyskinesia
- Key Features: Valbenazine is a VMAT2 inhibitor that helps regulate the release of neurotransmitters, such as dopamine, in the brain, improving movement disorder symptoms.
ORILISSA® (elagolix tablets)
- Indications: Treatment for endometriosis
- Key Features: Developed in collaboration with AbbVie, this product is used to manage moderate to severe pain associated with endometriosis.
ORIAHNN® (elagolix, estradiol, and norethindrone acetate capsules, and elagolix capsules)
- Indications: Management of heavy menstrual bleeding due to uterine fibroids in premenopausal women
- Key Features: This combination therapy targets hormone pathways that influence uterine fibroids.
Crinecerfont
- Indications: Investigational treatment for congenital adrenal hyperplasia (CAH)
- Key Features: Crinecerfont is a CRF1 receptor antagonist with potential to address CAH, a rare endocrine disorder.
Recent Developments
- INGREZZA New Indications: In 2023, valbenazine was approved for a second indication beyond tardive dyskinesia. Ongoing investigations continue to assess its efficacy in additional neurological and neuropsychiatric conditions.
- Research and Development: Neurocrine Biosciences continues to focus on movement disorders, epilepsy, congenital adrenal hyperplasia, and neuropsychiatric disorders, with several compounds in various stages of clinical trials.
- Partnerships: The company has a collaborative partnership with AbbVie for the development and commercialization of elagolix-based products.
Recent Financial and Operational Highlights
- Financial Results (Q3 2024): Neurocrine Biosciences reported its third-quarter financial results in October 2024, alongside raising the sales guidance for INGREZZA.
- Clinical Trials: Active clinical trials such as KINECT®-HD2 for Huntington’s disease and Journey™ Study for schizophrenia are ongoing, reflecting the company's strategic focus on expanding indications for existing medications.
Summary
Neurocrine Biosciences continues to build on its strong scientific foundation, driven by a mission to bring meaningful advances to those with serious, under-addressed medical conditions. With a robust pipeline and key partnerships, the company is well-positioned to maintain its leadership in the development of therapies for complex neurological and endocrine disorders.
